Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $4.5M of Stock

On October 23, 2026, Qiming Corporate GP VI, Ltd. sold 147,934 shares of Alamar Biosciences, Inc. for about $4.5 million. This sale reduced Qiming's stake by 7.74%, leaving it with 1,762,341 shares. The transaction was reported in a Form 4 filing with the SEC.

ALMR Alamar Biosciences, Inc.

$30.39 ▲ +17.43% past 3 months

1M 3M

Daily close · Oct 26, 2026

Inside Qiming Corporate GP VI's Trade

Qiming Corporate GP VI sold these shares at an average price of $30.59 on the day of the transaction. This sale follows a series of earlier trades where Qiming also sold significant shares of Alamar. On October 22, Qiming sold 133,811 shares, and prior to that, it sold 208,815 shares on October 21, and 142,004 shares on October 20. Overall, these transactions indicate a pattern of reducing its holdings in Alamar Biosciences.

Other Institutional Activity in Alamar Biosciences

Other institutional investors have also been active with Alamar Biosciences. Sands Capital Alternatives, LLC increased its holdings by 2,115,463 shares, bringing its total to 4,230,926 shares valued at about $135.1 million. Similarly, Samsara BioCapital, LLC added 1,240,155 shares for a total of 2,480,310 shares worth approximately $79.2 million. ARK Investment Management, LLC grew its stake by 686,980 shares, ending with 1,373,959 shares valued at about $43.9 million. Braidwell LP increased its holdings by 541,992 shares, totaling 1,083,983 shares worth around $34.6 million, while AllianceBernstein L.P. added 501,538 shares for a total of 1,003,077 shares valued at about $32.0 million.

Alamar Biosciences, Inc. Stock Up 5.1%

Alamar Biosciences closed at $30.69 on October 23, 2026. The stock is currently trading around $31.93, which is about 4% above its closing price on the day of Qiming's sale. The shares are above their 50-day moving average by about 3.9% and are also above their 200-day average by roughly 19.4%. However, they remain below the 52-week high of $39.61 by about 19.4%.

Recent Earnings

Alamar Biosciences reported trailing twelve-month revenue of $100.4 million, with a revenue growth of 82.1% year-over-year. The company has not been profitable, with a net margin of -49.5%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Alamar Biosciences, Inc.

Recently, Qiming Corporate GP VI has been active in selling its shares of Alamar. On October 19, it sold 75,508 shares for about $1.99 million. The following day, it sold 142,004 shares for approximately $3.96 million, and on October 21, it sold 208,815 shares valued at about $6.33 million. The insider activity shows a consistent pattern of divesting shares.

Analysts Set New Price Targets

On August 11, 2026, Stifel maintained a Buy rating on Alamar Biosciences with a price target of $32.00, up from $28.00. JP Morgan also maintained an Overweight rating with a price target of $35.00, increased from $32.00. The consensus among analysts currently is a Buy rating with a mean price target of $35.40.

About Alamar Biosciences, Inc.

Alamar Biosciences, Inc. specializes in developing a proteomic liquid biopsy platform. They create instruments, consumables, and services aimed at early disease detection. Their NULISA technology focuses on detecting and quantifying protein biomarkers, which is crucial for medical diagnostics. The company is headquartered in Fremont, California, and operates within the healthcare sector, specifically in medical devices.

Bottom Line

Investors will be watching Alamar's next earnings report scheduled for November 3, 2026. Additionally, further insider trading activity may provide insight into shareholder sentiment as Qiming Corporate GP VI continues to reduce its stake in the company.